Pharmacokinetics and pharmacodynamics of sacubitril/valsartan in peritoneal dialysis patients.

Yi HeYing JinHen XueRunhan LiuMengyu ZhangRuoxi LiaoMaoli ChenXueli ZhouXueqin HeMin QinKuo LiHuiqun ZouYing GanZhenlei WangLi ZhengHui ZhongPing Fu

Published in: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2023)

PD and residual renal function contributed only to a minor degree to the elimination of LBQ657. Additionally, a dose of 100 mg BID SV is safe and effective in patients with PD with complications of hypertension or HF.

Keyphrases

end stage renal disease
peritoneal dialysis
chronic kidney disease
ejection fraction
blood pressure
newly diagnosed
prognostic factors
risk factors
heart failure
atrial fibrillation
acute heart failure